465 CAR-Engineered Extracellular Vesicles From Human Stem Cell-Derived Neutrophils for Glioblastoma Therapy
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
INTRODUCTION: GBM is a lethal brain tumor with limited therapeutic options, hindered by the blood-brain barrier (BBB). Immune therapies employing chimeric antigen receptor (CAR)-engineered cells show promise but face limitations including immune suppression and off-target effects. Extracellular vesicles (EVs), derived from CAR-engineered neutrophils, may circumvent these issues while retaining targeted tumor cytotoxicity. METHODS: hPSCs were genetically engineered to express CLTX-CAR and differentiated into neutrophils. EVs were isolated at distinct differentiation stages (day 12 hematopoietic progenitors and day 21 neutrophils) via ultracentrifugation, characterized by nanoparticle tracking analysis, transmission electron microscopy, and western blot. Proteomic analysis and miRNA sequencing were conducted on EVs. Uptake and cytotoxicity of EVs were tested in vitro using GBM cell lines (U87MG, LN229) in 2D, apoptosis pathways were analyzed by RT-qPCR and results validated in 3D spheroid models. RESULTS: EV characterization confirmed typical exosomal properties with particle sizes of 150-300 nm and positive exosomal markers. Proteomic and miRNA analysis revealed enriched cargos that could potentially suppress cancer progression through miRNA-mediated regulation of critical genes like PTEN, MYC, and BCL2. CLTX-CAR neutrophil-derived EVs demonstrated effective BBB penetration and targeted GBM cell uptake, significantly reducing cell viability in a dose-dependent manner across both 2D. RT-qPCR analysis showed upregulated pro-apoptotic markers and tumor-suppressive genes (PTEN, p53). Findings were consistent in 3D spheroid models. CONCLUSIONS: CLTX-CAR hPSC-derived neutrophil EVs effectively target GBM cells, bypassing the BBB and inducing potent tumor cytotoxicity via apoptotic and tumor-suppressive cargo. These findings highlight CAR EVs as a novel, safer therapeutic alternative with significant translational potential for GBM treatment.
Fields of Study & Subjects
Extracellular vesicles in disease
Nanoparticle-Based Drug Delivery
Glioma Diagnosis and Treatment
Publication details
- Journal / source
- Neurosurgery
- Volume
- 72
- Issue
- Supplement_1
- Pages
- 136–136
- Publication date
- 26 March 2026
- Language
- EN